AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Therapies for Psychiatric Disorders
AbbVie has signed an option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders.
Psychiatric Disorders | 14/05/2024 | By Aishwarya | 601
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy